TABLE 1.

Activity of dalbavancin and selected Gram-positive focused agents when tested against resistance phenotypes of S. aureus from a worldwide surveillance program, 2002 to 2012

Organism/subset (no. tested)a	Antimicrobial agent	MIC (μg/ml)			% susceptibleb
		50%	90%	Range
All S. aureus (62,195)	Dalbavancin	0.06	0.06	≤0.008 to 0.5	99.7
MRSA (26,975)	Dalbavancin	0.06	0.06	≤0.008 to 0.5	99.6
	Daptomycin	0.25	0.5	≤0.06 to 4	99.9
	Vancomycin	1	1	≤0.12 to 4	99.9
	Linezolid	1	2	≤0.12 to 16	99.9
	Tigecyclinec	0.12	0.5	≤0.015 to 1	99.9
	Clindamycin	≤0.06	>2	≤0.06 to >8	60.3
Daptomycin NS (37)	Dalbavancin	0.06	0.12	≤0.03 to 0.5	91.9
	Vancomycin	2	2	1 to 4	94.6
	Linezolid	1	2	0.5 to 4	100.0
	Tigecycline	0.12	0.25	≤0.03 to 0.25	100.0
	Clindamycin	>2	>2	≤0.06 to >2	43.2
Linezolid R (19)	Dalbavancin	0.06	0.12	≤0.03 to 0.12	100.0
	Vancomycin	1	2	0.5 to 2	100.0
	Daptomycin	0.5	0.5	0.25 to 0.5	100.0
	Tigecycline	0.12	0.5	0.06 to 0.5	100.0
	Clindamycin	>2	>2	≤0.25 to >2	42.1
Tigecycline NS (38)	Dalbavancin	0.06	0.06	≤0.03 to 0.12	100.0
	Vancomycin	1	2	0.5 to 2	100.0
	Daptomycin	0.25	0.5	0.25 to 0.5	100.0
	Linezolid	2	2	1 to 2	100.0
	Clindamycin	>2	>2	≤0.06 to >2	26.3
MRSA from 2010–2012 (5,167)d	Dalbavancin	0.06	0.06	≤0.03 to 0.25	99.7
MDR (1,484)	Dalbavancin	0.06	0.06	≤0.03 to 0.25	99.8
	Vancomycin	1	1	≤0.12 to 2	100.0
	Daptomycin	0.25	0.5	0.12 to 2	99.8
	Linezolid	1	1	≤0.12 to 8	99.8
	Tigecyclined	0.12	0.25	≤0.03 to 1	99.8

^aMRSA, methicillin-resistant S. aureus; NS, nonsusceptible; R, resistant; MDR, multidrug resistant.

^bAccording to breakpoint criteria of the CLSI (7) and U.S. FDA (4, 10), where appropriate.

^cData not available for 2011 isolates; n = 26,436.

^dIsolates from 2010 and 2012 were tabulated (1,332 MDR isolates).